Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights.
asbestos
malignant mesothelioma
molecular pathways
peritoneal mesothelioma
prognostic factors
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
11
2021
accepted:
17
01
2022
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
1
3
2022
Statut:
epublish
Résumé
Mesothelioma is a rare malignant neoplasm with poor survival. It mainly affects the pleura (90%) but can arise in all serous cavities: peritoneum (5-10%), pericardium and tunica vaginalis testis (<1%). The onset of pleural mesothelioma is strictly related to asbestos exposure with a long latency time. The causal link with asbestos has also been suggested for peritoneal mesothelioma, while the importance of exposure in the onset of pericardial and tunica vaginalis testis mesotheliomas is not well known. Mesothelioma remains an aggressive and fatal disease with a five-year mortality rate higher than 95%. However, new therapeutic approaches based on molecular-targeted and immunomodulatory therapies are being explored but have conflicting results. In this context, the identification of critical targets appears mandatory. Awareness of the molecular and physiological changes leading to the neoplastic degeneration of mesothelial cells and the identification of gene mutations, epigenetic alterations, gene expression profiles and altered pathways could be helpful for selecting targetable mechanisms and molecules. In this review, we aimed to report recent research in the last 20 years focusing on the molecular pathways and prognostic factors in peritoneal mesothelioma and their possible diagnostic and therapeutic implications.
Identifiants
pubmed: 35223506
doi: 10.3389/fonc.2022.823839
pmc: PMC8866824
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
823839Informations de copyright
Copyright © 2022 Fortarezza, Pezzuto, Marzullo, Cavone, Romano, d’Amati, Serio and Vimercati.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mod Pathol. 2020 Nov;33(11):2269-2279
pubmed: 32504035
EBioMedicine. 2019 Jan;39:215-225
pubmed: 30581150
Eur J Surg Oncol. 2021 Jan;47(1):36-59
pubmed: 32209311
Br J Cancer. 2021 Feb;124(3):564-566
pubmed: 33100328
Mod Pathol. 2017 Feb;30(2):246-254
pubmed: 27813512
Int J Mol Sci. 2016 May 14;17(5):
pubmed: 27187383
Front Oncol. 2021 Mar 22;11:653497
pubmed: 33828993
J Clin Oncol. 2018 Oct 1;36(28):2863-2871
pubmed: 30113886
Ann Surg Oncol. 2006 Mar;13(3):405-12
pubmed: 16485159
Oncotarget. 2016 Nov 15;7(46):75503-75517
pubmed: 27705913
Medicine (Baltimore). 2016 Nov;95(48):e5447
pubmed: 27902597
Int J Gynecol Pathol. 2022 Jan 1;41(1):59-67
pubmed: 33577225
Am J Case Rep. 2017 Jun 5;18:632-636
pubmed: 28579603
J Clin Med. 2019 Mar 26;8(3):
pubmed: 30917582
J Thorac Dis. 2019 Jan;11(Suppl 1):S102-S112
pubmed: 30775033
Arch Pathol Lab Med. 2018 Jan;142(1):89-108
pubmed: 28686500
Oncol Rep. 2012 Jun;27(6):1794-800
pubmed: 22426987
Genomics Inform. 2021 Jun;19(2):e16
pubmed: 34261301
Histopathology. 2016 Mar;68(4):603-7
pubmed: 26179668
Mod Pathol. 2019 Jan;32(1):88-99
pubmed: 30171198
Int J Mol Sci. 2017 Aug 22;18(8):
pubmed: 28829357
Arch Pathol Lab Med. 2013 May;137(5):647-67
pubmed: 22929121
Am J Surg Pathol. 2020 Feb;44(2):288-292
pubmed: 31567203
Occup Environ Med. 1994 Dec;51(12):804-11
pubmed: 7849863
Ultrastruct Pathol. 2016 May-Jun;40(3):134-41
pubmed: 27281118
Tumour Biol. 2012 Dec;33(6):2031-40
pubmed: 22836805
Cancer Biol Ther. 2016;17(3):328-35
pubmed: 26853494
Cancer. 2011 Jan 15;117(2):361-71
pubmed: 20839315
Anticancer Res. 2016 May;36(5):2331-8
pubmed: 27127140
Genes Chromosomes Cancer. 2013 Aug;52(8):733-40
pubmed: 23630070
Cancer. 2020 Nov 15;126(22):4936-4947
pubmed: 32870522
J Clin Oncol. 2020 Jun 1;38(16):1824-1835
pubmed: 32213105
Ann Oncol. 2018 May 1;29(5):1258-1265
pubmed: 29514216
Int J Mol Sci. 2019 Nov 19;20(22):
pubmed: 31752449
Genome Med. 2019 Feb 18;11(1):8
pubmed: 30777124
World J Surg Oncol. 2010 Oct 13;8:88
pubmed: 20942962
Oncogene. 2012 Dec 6;31(49):5117-22
pubmed: 22286761
Am J Surg Pathol. 2020 Mar;44(3):293-304
pubmed: 31876584
Eur J Cancer. 2010 Oct;46(15):2837-48
pubmed: 20692828
Hum Pathol. 2019 Jan;83:199-203
pubmed: 30118736
Cancer. 2014 Nov 1;120(21):3311-9
pubmed: 24989332
Cancers (Basel). 2021 May 10;13(9):
pubmed: 34068638
Chest. 2000 Feb;117(2):486-93
pubmed: 10669695
Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2):
pubmed: 30862609
Lung Cancer. 2018 Dec;126:106-111
pubmed: 30527173
Carcinogenesis. 2013 Jul;34(7):1413-9
pubmed: 23677068
BMC Cancer. 2015 Jan 15;15:8
pubmed: 25588929
BMC Med Genet. 2018 Aug 15;19(1):144
pubmed: 30111295
Cancer Med. 2016 May;5(5):950-9
pubmed: 26860323
Lancet Respir Med. 2021 Jun;9(6):593-600
pubmed: 33515503
Mod Pathol. 2020 Feb;33(2):217-227
pubmed: 31570769
Diagnostics (Basel). 2020 Jun 09;10(6):
pubmed: 32526924
JCO Precis Oncol. 2019 Jul 11;3:
pubmed: 32914035
Am J Surg Pathol. 2017 Jul;41(7):980-988
pubmed: 28505004
ESMO Open. 2017 Apr 12;2(1):e000101
pubmed: 28761723
Occup Environ Med. 2019 Aug;76(8):545-553
pubmed: 31285358
JAMA Oncol. 2018 Feb 1;4(2):235-238
pubmed: 28910456
Br J Cancer. 2021 Oct;125(8):1039-1055
pubmed: 34226685
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
J Transl Med. 2015 Apr 16;13:122
pubmed: 25889843
Int J Mol Sci. 2020 Sep 01;21(17):
pubmed: 32882916
PLoS One. 2015 Mar 23;10(3):e0119689
pubmed: 25798586
Oncologist. 2021 May;26(5):356-361
pubmed: 33555117
J Thorac Oncol. 2017 Apr;12(4):724-733
pubmed: 28034829
Mod Pathol. 2016 Jan;29(1):14-24
pubmed: 26493618